Zynlonta (Loncastuximab Tesirine-Lpyl) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Zynlonta is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes conditions such as diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. Zynlonta is also known by its drug name, loncastuximab tesirine-lpyl.

Zynlonta belongs to a class of medications known as antibody-drug conjugates. It’s believed to work by combining an antibody that targets CD19, a protein found on the surface of certain B cells, with a chemotherapy drug. The antibody component binds to CD19-expressing cells, delivering the chemotherapy directly to the cancerous cells.

How do I take it?
According to prescribing information, Zynlonta is administered as an intravenous infusion over 30 minutes on Day 1 of each three-week cycle. People taking the medication should be premedicated with dexamethasone twice daily for 3 days, beginning the day before receiving Zynlonta, per the prescribing information. It is essential to take this medication exactly as prescribed by a health care provider.

Side effects
Common side effects of Zynlonta include thrombocytopenia (low platelet count), increased gamma-glutamyltransferase levels, neutropenia (low white blood cell count), anemia (low red blood cell count), hyperglycemia (high blood sugar), elevated transaminase levels, fatigue, hypoalbuminemia (low albumin levels), rash, edema (swelling), nausea, and musculoskeletal pain.

Rare but serious side effects may include effusion and edema, myelosuppression (decreased bone marrow activity), infections, skin reactions (including light sensitivity), and harm to an unborn fetus if taken while pregnant. 

For more information about this treatment, visit:

Label: Zynlonta — Loncastuximab Tesirine Injection, Powder, Lyophilized, for Solution — DailyMed

Loncastuximab Tesirine-Lpyl Injection — MedlinePlus

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in